Craddick files House Bill 5 to establish the Dementia Prevention and Research Institute of Texas
Feb. 25—AUSTIN — Representative Tom Craddick has filed House Bill 5 to create the Dementia Prevention and Research Institute of Texas (DPRIT), a groundbreaking initiative aimed at advancing research, prevention, and treatment strategies for Alzheimer's.
"Alzheimer's is a growing crisis that affects countless Texans and their families. We must take bold action to combat this disease," said Craddick. "HB 5 establishes a dedicated institute to drive research, develop prevention programs, and support groundbreaking medical advancements that will improve the lives of Texans."
The Dementia Prevention and Research Institute of Texas will fund and accelerate research into the causes, prevention, and treatment of dementia, Alzheimer's, and related disorders while supporting medical and scientific breakthroughs that enhance Texas' leadership in medical research. The institute will award grants to institutions of higher education, medical research facilities, and other public or private entities dedicated to combating Alzheimer's. Additionally, it will develop prevention programs aimed at reducing the impact of dementia on Texas communities.
"Texas ranks third in the nation in the number of Alzheimer's cases and second in the nation in Alzheimer's deaths. The establishment of this institute will provide hope to all future generations that Texas will be a leader in Alzheimer's Prevention," added Craddick.
The Texas Legislative Session began on January 14, 2025, and will run through June 2, 2025. HB 5 represents a major step in addressing one of the most pressing healthcare challenges of our time.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Rosemary, sage could boost brain health: Study
(NewsNation) — A recent study has found that rosemary and sage may have a positive impact on brain health and reduce the risk of Alzheimer's disease. The study released in the Antioxidants journal shows a compound shared by the two herbs called carnosic acid has antioxidant and anti-inflammatory properties that shield brain cells from damage similar to what can lead to Alzheimer's. Researchers were able to create a more stable form of carnosic acid called diAcCA. Screen time a symptom, cause of emotional distress in kids: Study In preclinical studies, the researchers found that the compound improved memory, boosted brain synapses and reduced harmful Alzheimer's-related proteins like amyloid-beta and tau. The diAcCA compound only activates in inflamed brain regions, which could minimize side effects. To date, studies in mice have shown significant cognitive improvements and no signs of toxicity. Researchers are looking to start human trials soon. Researchers also believe diAcCA could help treat other inflammatory conditions, such as Type 2 diabetes, cardiovascular disease and Parkinson's disease. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Fast Company
8 hours ago
- Fast Company
Enough hype about AI in health—let's talk about results
There's no shortage of big promises about AI in healthcare. The U.S. government announced a $500 billion Stargate initiative to fund AI infrastructure, while the UK government announced £82.6 million in research funding for three projects, two of which are using AI to tackle cancer and Alzheimer's disease. But ask any patient waiting for a diagnosis, or a clinician searching for certainty, and the real question cuts through all the noise: When will all the innovation deliver real impact where it matters most? We've entered an era where healthcare data is measured in exabytes—genomes, images, clinical notes, labs, and signals from every continent. At SOPHiA GENETICS, we've just achieved the milestone of analyzing 2 million patient profiles. It's a number that was unimaginable a decade ago. Yet the value of data isn't in volume. It's what you do with it. Insight matters only if it changes an outcome, shortens a diagnostic odyssey, or opens up a new chance for a patient. It's time to move from conversation to action. Too often, insights get trapped in institutional silos or left in endless pilot projects, just out of reach of the people who need them. 3 ways AI is already transforming medicine Today, technology can connect, for example, a patient in São Paulo with expertise in Seoul, uncovering patterns invisible to the human eye. Here are several ways AI is helping now. 1. Improving diagnostic accuracy: AI algorithms, particularly those based on deep learning, have demonstrated remarkable accuracy in diagnosing diseases from medical images and test results. These systems are trained on vast datasets, allowing them to recognize patterns and anomalies that might be missed by the human eye. For example, in dermatology, AI systems trained on images of skin lesions have shown the ability to detect skin cancers, such as melanoma, with high levels of precision. 2. Enhancing cancer prevention: AI techniques can be used to screen individuals for genomic markers and develop personalized cancer risk prediction scores. This proactive approach can help screen younger patients for genomic predispositions, empowering them to make informed prevention decisions and proactively monitor their health. 3. Tailoring treatments to genomic profiles: One of the most significant applications of AI is in the field of genomics. AI can analyze vast genomic datasets to identify mutations and variations that might influence an individual's response to certain treatments. For example, our SOPHiA DDM product can identify specific genomic markers that are susceptible to targeted cancer therapies, increasing the efficacy of the treatment and minimizing the risk of adverse reactions, for a more effective and safer treatment plan for patients. To scale up these AI applications there are many regulatory and compliance barriers to overcome. This requires investment in data security, creating clear guidelines, data security measures, and ensuring clinicians are fully trained. Our goal should be to create a regulatory environment that fosters innovation while safeguarding patient data and promoting public trust. We must democratize this powerful data to enable more physicians, practices, and hospitals to incorporate AI into daily clinical use so that a greater number of patients can access data-driven medicine, not just a select few. My message for governments investing in AI is clear: Balance investing in future AI tools with validating existing solutions that have already been proven to improve patient outcomes. Build the bridges that turn breakthroughs into benefits, so that data-driven medicine becomes a reality for every patient.
Yahoo
9 hours ago
- Yahoo
Illinois becomes first state to require that all insurance covers Alzheimer's treatment
SPRINGFIELD, Ill. (WCIA) — Illinois is making a major expansion in patient care and access to new treatment for Alzheimer's, thanks to a new state law taking effect in July 2025. Gov. J.B. Pritzker signed a bill that will require state health insurance to cover U.S. Food and Drug Administration (FDA) approved medicine to slow down Alzheimer's and other related diseases. SEE ALSO: New Illinois laws and tax changes set to kick in on July 1, 2025 Some Alzheimer's patients will no longer have to go through step therapy — a process where insurers require patients to try and test less expensive drugs before covering the actual medication prescribed by their doctor. The Alzheimer's Association Illinois Chapter, which has been a forefront advocate for this, called the law 'groundbreaking.' 'For people living with Alzheimer's, slowing the progression of the disease changes someone's life — not only that individual's life, but the lives of their caregivers and all those around them, family and friends,' said David Olson, Director of State Affairs at the Alzheimer's Association Illinois Chapter. This coverage will also include diagnostic testing at the doctor's request. This ensures patients can access an accurate diagnosis before even starting the treatment. In 2020, there were 230,000 seniors with Alzheimer's disease or a related dementia in the state, and according to the Illinois Department of Health, that number is expected to increase to 260,000 this year. With the rise in medical costs, insurance coverage is essential for most families. Bill creating Office of State Public Defender heads to Pritzker's desk The bill's sponsor in the House, Rep. Mary Gill (D-Chicago), said with dementia, time is always at the essence. 'When it comes to slowing Alzheimer's and other dementias, every moment counts,' Gill said. 'We can't waste time on insurance gimmicks like step therapy to save a few bucks, which is why I'm thankful for the strong advocacy and bipartisan support this legislation received.' Other private insurance plans will also begin covering FDA-approved treatment starting in 2027. 'We worked collaboratively with the insurance industry on this legislation,' Olson said. 'We were able to find and agree upon language here that expands access in a way that also isn't increasing cost to consumers.' Currently, there are two types of treatments for Alzheimer's approved by the FDA. One is Lecanemab, and the other is Donanemab. These will not end the disease, as there is currently no cure for Alzheimer's. This law makes Illinois the first state to require such treatment, and advocates said they hope other states will follow its lead. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
